New TB drug cocktail aims to shorten treatment
NCT ID NCT06058299
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether a new drug called TBAJ-876, or the existing drug bedaquiline, combined with pretomanid and linezolid, can treat drug-sensitive tuberculosis faster and more effectively than the standard 6-month regimen. About 309 adults with newly diagnosed TB are taking part. The study compares how quickly the bacteria clear from sputum and checks safety over 26 weeks of treatment plus 52 weeks of follow-up.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TBAJ-876 (also called sorfequiline), bedaquiline, pretomanid, linezolid, and standard TB drugs (isoniazid, rifampicin, pyrazinamide, ethambutol)
What this could lead to
If successful, this could lead to a shorter, simpler treatment regimen for drug-sensitive tuberculosis, potentially replacing the current standard of care.
What could go wrong
This is a Phase 2 trial with only 309 participants, so results may not apply to everyone. The new drug combinations may cause side effects like nerve damage or heart rhythm issues, and they might not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Care Clinical Trial Group Inc.
Dasmariñas, 4114, Philippines
-
Case Western Reserve University- Research collaboration Uganda
Kampala, Uganda
-
Desmond Tutu Health Foundation
Cape Town, 7750, South Africa
-
Enhancing Care Foundation
Durban, 4052, South Africa
-
Isango Lethemba TB Research Unit
Port Elizabeth, 6200, South Africa
-
Joint Clinical Research Centre (JCRC)
Kampala, Uganda
-
Kilimanjaro Christian Medical Centre
Moshi, Tanzania
-
Lung Center of the Philippines
Quezon City, 1104, Philippines
-
Madibeng Centre for Research
Brits, 0250, South Africa
-
NIMR-MBEYA Medical Research Center
Mbeya, Tanzania
-
National Center for Tuberculosis and Lung Diseases
Tbilisi, 0101, Georgia
-
National Institute for Medical Research (NIMR)
Mwanza, Tanzania
-
Perinatal HIV Research Unit (PHRU)
Klerksdorp, 2571, South Africa
-
Setshaba Research Centre
Soshanguve, Gauteng, 0152, South Africa
-
Synergy Biomed Research Institute (SBRI)
East London, 5201, South Africa
-
TASK Brooklyn
Cape Town, 7405, South Africa
-
TASK Eden
George, 6529, South Africa
-
TB and HIV Investigative Network (THINK)
Hillcrest, 3610, South Africa
-
The Aurum Institute
Rustenburg, 2999, South Africa
-
Tropical Disease Foundation
Makati City, 1230, Philippines
-
University of Cape Town Lung Institute (UCTLI)
Cape Town, 7700, South Africa
-
WITS, Clinical HIV Research Unit (CHRU) Themba Lethu Clinic, Helen Joseph Hospital
Johannesburg, 2092, South Africa